Feb 24 Intersect Ent Inc
* Intersect ENT announces FDA approval of newest steroid releasing implant, Propel Contour, for use in treating the frontal and maxillary sinuses
* Intersect ENT Inc - expects to launch propel contour broadly in Q2 of 2017 and maintains its previously stated 2017 revenue guidance of $87-$89 million
* FY2017 revenue view $88.0 million -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:
GLOBAL MARKETS-Asia stocks edge up on optimism over global growth, dollar soft
TOKYO, June 26 Asian shares edged up on Monday on optimism for global growth, while the dollar was on the defensive as a subdued U.S. inflation outlook capped U.S. bond yields and raised questions about the Federal Reserve's plans to tighten policy.